Mylan personnel appointments
Executive Summary
VP-Generic Business Development John Deiriggi is appointed to the new position of chief operating officer of Mylan's generic subsidiary, Mylan Pharmaceuticals, the company announces. Deiriggi is a 19-year veteran of Mylan. In connection with the promotion, Exec Director of Corporate Administration Daniel Caron will take over as VP of generic business development. Additional moves include Gary Sphar to the post of exec VP and CFO of Mylan Pharmaceuticals and Brian Roman to the post of VP and general counsel of the generic subsidiary...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.